Research programme: tubulin binders - Novuspharma

Drug Profile

Research programme: tubulin binders - Novuspharma

Alternative Names: Tubulin binders research programme - Novuspharma

Latest Information Update: 07 Jan 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novuspharma
  • Class
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Colorectal cancer

Most Recent Events

  • 07 Jan 2004 Novuspharma has since merged with and into the US company Cell Therapeutics
  • 08 Sep 2003 Discontinued - Preclinical for Colorectal cancer in Italy (unspecified route)
  • 24 Oct 2001 Preclinical development for Colorectal cancer in Italy (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top